Pharmacotherapy Considerations in Advanced Cardiac Life Support

Several approaches can be used to manage symptomatic bradycardia.
This includes use of an internal or external pacesetter or drug therapy, either by increasing the rate of conduction by stimulating ?1-adrenergic natural action with catechola-mines or by blocking parasympathetic state with atropine.Atropine
Atropine inhibits cholinergic responses that diminish courage rate and systemic vascular resis-tance, and is recommended for use in patients with symptomatic bradycardia, PEA with bradycardia, and asystole. Supporting data are limited and unclear in footing of the potency of atropine for asystole.
One size prospective acquisition in 21 patients found no significant dispute in the rate of successful resuscitation in patients who received atropine and in those who did not (control group). A large retrospective depth psychology in 170 patients with asystole that was resistant to epinephrine found a significantly higher rate of resuscitation associated with atropine (14%) compared with medication (0%).
The recommended dose of atropine for the governance of asystole or PEA associated with bradycardia is 1 mg intravenously, repeated every 3–5 minutes, for a limit dose of 3 mg. The ILCOR guidelines suggest a unity 3-mg intravenous dose in patients with asystole or PEA associated with bradycardia. Doses exceeding the uttermost may final result in aggregate vagal military action.
For the organization of symptomatic bradycardia, the recommended medicinal drug is 0.5 mg every 3–5 minutes (3 mg maximum). Higher doses, starting at 2–4 mg, are suggested if an organophosphate, carbamate, or brass broker putting to death is nowadays. Slow infusions of atropine or organism doses less than 0.5 mg should be avoided, as these have been associated with a paroxysmal parasympathetic result, further slowing the courage rate and exacerbating the bradycardia.
Atropine organisation in the attending of second-degree atrioventricular blockage Mobitz type II should be performed cautiously because of the theoretic potential drop for atropine to exacerbate the atrioventricular aggregation by accelerating the atrial rate. Atropine should be used with attentiveness in patients with acute coronary syndromes, formation to potentiality increases in ischemia and zone of infarction from elevated warmness rates. Atropine should also be used cautiously in patients with denervated hearts after transplant.
There is some limited info suggesting that aminophylline may be a promising grammatical construction in patients with atropine-resistant atrioventricular stoppage (250 mg intravenously over 10 min) or atropine-resistant asystole (250-mg intravenous bolus). Atropine 2–2.5 mg may be administered through an endotracheal tube if intravenous way is not available.
This is a part of article Pharmacotherapy Considerations in Advanced Cardiac Life Support Taken from "Atropisol - Atropine Information" Information Blog